Treatment of Juvenile Idiopathic Arthritis: What's New?

Gabriella Giancane; Nicolino Ruperto; for the Paediatric Rheumatology International Trials Organisation (PRINTO)

Disclosures

Curr Opin Rheumatol. 2019;31(5):428-435. 

In This Article

Abstract and Introduction

Abstract

Purpose of review: The present review highlights the advances in disease outcome achieved with currently available biologic medications and future perspectives for JIA management.

Recent findings: In the last two decades, the management of juvenile idiopathic arthritis (JIA) has been revolutionized by appropriate legislative initiatives, the existence of very large collaborative networks and the increased availability of the novel biologic medications.

Summary: A more rational approach to the management of JIA is being fostered by the recent publication of therapeutic recommendations, consensus treatment plans and for a treat-to-target strategy.

Introduction

Juvenile idiopathic arthritis (JIA)[1,2] is a heterogeneous group of conditions, which encompasses all forms of arthritis of unknown cause, lasting for at least 6 weeks, with onset before the age of 16 years. The diagnosis, because of the lack of a single pathognomonic clinical or laboratory feature, is still clinical and based on the International League Against Rheumatism (ILAR) classification (Table 1), which recognizes six different categories of JIA, whose features develop during the first 6 months of illness,[3,4] although an updated classification has been recently proposed.[5] Indeed, the treatment of JIA has improved tremendously in the last 20 years, thanks to appropriate legislative initiatives, the existence of very large collaborative networks, such as the Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG), and the availability of new potent medications, in particular the biological disease-modifying antirheumatic drugs (DMARDs).[6,7]

Comments

3090D553-9492-4563-8681-AD288FA52ACE

processing....